Table 4 Summary of Patients outcome and other factors
From: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Characteristics | Lapatinib plus capecitabine Median PFS (months) | P value |
|---|---|---|
Age, (yrs) | Â | Â |
   <49 yr | 6 | 0.283 |
   ≥49 yr | 10 |  |
EOCG performance status | Â | Â |
   0 | 10 | 0.174 |
   1 or 2 | 6.5 |  |
Hormone receptor status | Â | Â |
   ER(+) or PR(+) or Both | 6.5 | 0.529 |
   ER(-) and PR(-) | 7 |  |
HER2 expression by IHC | Â | Â |
   1+/2+ (HER2 status confirmed by FISH) | 6 | 0.963 |
   3+ positive | 7 |  |
Number of involved sites | Â | Â |
   1 or 2 | 8.5 | 0.249 |
   ≥3 | 6.5 |  |
Location of involved sites | Â | Â |
   Visceral only | 6.5 | 0.544 |
   Visceral and nonvisceral | 7.0 |  |
   Nonvisceral only | 7.0 |  |
Previous chemotherapy regimens | Â | Â |
   1 or 2 | 10 | 0.078 |
   ≥3 | 6.5 |  |
Previous capecitabine | Â | Â |
   YES | 6.5 | 0.011 |
   NO | 11 |  |